Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-V: Prophylaxis for COVID-19 in Vulnerable Patients
NCT04870333Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Feb 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of niclosamide, sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Feb 2021; status: completed.
02
Drugs
niclosamidesotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04870333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870333.